Treats active duodenal ulcer. ANDA 205868, held by Adaptis. Lansoprazole.
As of Nov 21, 2026, ANDA 205868 (Lansoprazole), held by Adaptis, was first approved by FDA on Aug 30, 2017, with 5 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Lansoprazole delayed-release capsules are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults Eradication of H.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2017 | Original application | Approved | None posted |
| Lansoprazole15MG ยท capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG ยท capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Nov 5, 2026 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Nov 5, 2026 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Nov 5, 2026 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Mar 3, 2020 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Mar 3, 2020 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Aug 30, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters